Mirabaud & Cie SA Makes New Investment in BioNTech SE (NASDAQ:BNTX)

Mirabaud & Cie SA bought a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the 4th quarter, HoldingsChannel reports. The fund bought 6,000 shares of the company’s stock, valued at approximately $684,000.

Other large investors have also recently bought and sold shares of the company. Planning Capital Management Corp lifted its holdings in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. grew its stake in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after buying an additional 111 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new stake in shares of BioNTech during the third quarter valued at $210,000. Finally, Probity Advisors Inc. purchased a new stake in BioNTech during the third quarter valued at about $216,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Trading Up 4.8 %

NASDAQ BNTX opened at $117.25 on Wednesday. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a market cap of $28.11 billion, a price-to-earnings ratio of -55.83 and a beta of 0.18. The business has a 50 day moving average price of $114.97 and a 200-day moving average price of $105.25. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.73 EPS. As a group, equities analysts expect that BioNTech SE will post -3.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. dropped their target price on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a report on Tuesday, November 26th. TD Cowen lowered their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. Wells Fargo & Company initiated coverage on shares of BioNTech in a research note on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. Finally, Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.